Clinical Trial Update: Nivolumab With DC Vaccines for Recurrent Brain Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating nivolumab in combination with dendritic cell vaccines for recurrent brain tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma
• Malignant Glioma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Gary Archer Ph.D. | Conditions: Malignant Glioma, Astrocytoma | Phase 1 | Status: COMPLETED | Results posted: 2020-03-26